CD44 is a glycoprotein involved in cell–cell signalling, migration and adhesion as well as in malignant tumor initiation; moreover, it is involved in several tyrosine kinases activation such as ERBB2 and TGFβ, that have been implicated in key oncogenesis pathways, this marker is also associated with stem cancer cells in human STS (Henderson et al. 2018) and predicts worse oncologic outcomes. This evidence concerns the gene CD44 and cancer.